Farxiga (Dapagliflozin) Dosing in Renal Impairment

How Dapagliflozin Works in Healthy and Impaired Kidneys

Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney. In a healthy nephron, SGLT2 handles roughly 90% of filtered glucose reabsorption. Blocking this transporter forces excess glucose into the urine, lowering blood glucose without depending on insulin secretion 1.

The glucose-lowering effect diminishes as kidney function declines because fewer functioning nephrons means less filtered glucose available for SGLT2 to reabsorb. At an eGFR of 30 mL/min/1.73 m², the glycemic benefit is minimal. This created early confusion. Clinicians assumed that reduced glucose lowering meant reduced clinical benefit, and early FDA labeling reinforced this by restricting initiation to eGFR ≥45 for the diabetes indication 2.

That assumption was wrong. Dapagliflozin's kidney and heart benefits operate through mechanisms independent of glucose lowering. The drug reduces intraglomerular pressure by restoring tubuloglomerular feedback, activating the macula densa signal that constricts the afferent arteriole 3. It also reduces tubular workload and oxygen consumption, lowers albuminuria, and decreases markers of inflammation and fibrosis. These hemodynamic and metabolic effects persist at low eGFR ranges where glycemic effects have already faded 4.

FDA-Approved eGFR Thresholds: A Moving Target

The FDA has revised dapagliflozin's renal thresholds three times since its 2014 approval, each time expanding access to patients with lower kidney function. The original label restricted initiation to eGFR ≥60 mL/min/1.73 m² for the type 2 diabetes indication. In 2019, following cardiovascular outcome data, this dropped to eGFR ≥45 2.

The key shift came in April 2021. Based on DAPA-CKD results, the FDA approved dapagliflozin for chronic kidney disease at risk of progression, with an initiation threshold of eGFR ≥25 mL/min/1.73 m². The same update lowered the diabetes initiation threshold to match 5.

The heart failure indication, approved in May 2020 for HFrEF and later expanded to HFpEF, carries no eGFR floor on the prescribing label. The dose is 10 mg once daily across all three indications, with no renal dose adjustment required at any eGFR level 2.

A practical point: the label distinguishes between initiation and continuation. A patient who starts dapagliflozin at eGFR 30 and later declines to eGFR 18 should continue the drug. Discontinue only when the patient begins maintenance dialysis or receives a kidney transplant.

DAPA-CKD: The Trial That Changed Renal Thresholds

DAPA-CKD (N=4,304) enrolled adults with CKD stages 2 through 4 and a urine albumin-to-creatinine ratio of 200 to 5 to 000 mg/g 3. Participants had eGFR between 25 and 75 mL/min/1.73 m². Roughly one-third did not have diabetes, making this the first SGLT2 inhibitor trial to demonstrate kidney protection independent of glycemic status.

The primary composite endpoint (sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death) occurred in 9.2% of the dapagliflozin group versus 14.5% with placebo over a median 2.4 years, yielding a hazard ratio of 0.61 (95% CI, 0.51 to 0.72; P<0.001) 3. The trial was stopped early for overwhelming efficacy.

Among participants with eGFR 25 to 45 at baseline (the lowest stratum), the hazard ratio for the primary endpoint was 0.73 (95% CI, 0.53 to 1.02), maintaining a consistent direction of benefit even at the lowest enrolled kidney function 6. The benefit in non-diabetic CKD was equally strong (HR 0.50; 95% CI, 0.35 to 0.72), confirming that glucose lowering is not the mechanism driving renal protection.

Dr. Hiddo Heerspink, the DAPA-CKD principal investigator, stated: "The results show that dapagliflozin provides kidney protection across a wide range of eGFR values, including patients with substantially reduced kidney function who were previously excluded from SGLT2 inhibitor use" 3.

DAPA-HF and Kidney Function Subgroups

DAPA-HF (N=4,744) randomized patients with heart failure and ejection fraction ≤40% to dapagliflozin 10 mg or placebo 1. The trial required eGFR ≥30 mL/min/1.73 m² at enrollment. The primary composite of worsening heart failure or cardiovascular death was reduced by 26% (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001).

Roughly 41% of DAPA-HF participants had eGFR <60 mL/min/1.73 m² at baseline 7. A prespecified subgroup analysis showed no interaction between baseline eGFR category and treatment effect (P for interaction = 0.87). Patients with eGFR 30 to 60 derived the same relative risk reduction as those with eGFR ≥60.

Dapagliflozin also slowed the rate of eGFR decline in DAPA-HF participants. The annual rate of eGFR change was -1.09 mL/min/1.73 m² per year with dapagliflozin versus -2.85 mL/min/1.73 m² per year with placebo (difference: 1.76 mL/min/1.73 m² per year; P<0.001) 7. This kidney-protective effect was observed despite heart failure, not CKD, being the primary enrollment criterion.

KDIGO 2024 Guidelines: Initiation at eGFR ≥20

The 2024 KDIGO Clinical Practice Guideline for CKD Evaluation and Management recommends initiating SGLT2 inhibitors (dapagliflozin or empagliflozin) in patients with CKD and eGFR ≥20 mL/min/1.73 m², regardless of diabetes status or albuminuria level 8. This threshold is 5 mL/min lower than the FDA label permits for dapagliflozin initiation.

The KDIGO recommendation is a 1A rating (strong recommendation, high-quality evidence). The guideline explicitly states: "Once an SGLT2 inhibitor is initiated, it is reasonable to continue the SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m², unless it is not tolerated or kidney replacement therapy is initiated" 8.

This creates a small but clinically relevant discrepancy. A nephrologist following KDIGO may initiate dapagliflozin at eGFR 22, while the FDA label restricts initiation to eGFR ≥25. In practice, many nephrologists follow the KDIGO threshold because the EMPA-KIDNEY trial (empagliflozin) enrolled patients with eGFR as low as 20 and showed consistent benefit 9. Off-label initiation between eGFR 20 and 24 is becoming standard nephrology practice.

The Initial eGFR Dip: Expected Hemodynamic Effect

Clinicians who are new to SGLT2 inhibitor prescribing often stop dapagliflozin when they see a 3 to 5 mL/min/1.73 m² decline in eGFR during the first two to four weeks. This is the wrong response. The early dip reflects reduced intraglomerular pressure (afferent arteriolar constriction via tubuloglomerular feedback restoration), not structural kidney damage 10.

The pattern is analogous to ACE inhibitor or ARB initiation, where an early creatinine rise of up to 30% is considered acceptable and even expected. In DAPA-CKD, the initial eGFR dip was approximately 3.97 mL/min/1.73 m² over the first two weeks, followed by stabilization and a slower long-term eGFR decline compared to placebo 3. By month 4, the dapagliflozin group's eGFR trajectory had crossed above the placebo trajectory.

A 2023 post-hoc analysis of DAPA-CKD data found that patients with a larger initial eGFR dip (≥10% from baseline) had equivalent long-term kidney protection compared to those with a smaller dip 6. Do not discontinue dapagliflozin solely because of this expected hemodynamic signal.

Stop the drug and reassess only if eGFR drops by more than 30% from baseline in the first month, the patient develops symptomatic hypotension or volume depletion, or there is a clear alternative explanation for acute kidney injury (sepsis, obstruction, nephrotoxin exposure).

Practical Dosing Protocol for Renal Impairment

The dose is 10 mg once daily. There is no 5 mg maintenance dose for dapagliflozin (unlike empagliflozin, which comes in 10 mg and 25 mg). No dose titration is needed 2.

Before initiation, check baseline eGFR, serum potassium, urine albumin-to-creatinine ratio, and volume status. Patients on loop diuretics may need a 25% to 50% dose reduction of the diuretic at SGLT2 inhibitor initiation to prevent volume depletion, particularly if eGFR is <45 8.

Recheck serum creatinine and potassium at 2 to 4 weeks after initiation. Expect the eGFR dip. If eGFR has dropped <30% and the patient is asymptomatic, continue. For patients on concurrent ACE inhibitors or ARBs (as most CKD patients will be), the additive hemodynamic effect may cause a slightly larger initial dip. This combination is safe and recommended by KDIGO as the standard of care for proteinuric CKD 8.

Monitor eGFR at 3 months, then every 3 to 6 months per CKD stage-appropriate intervals. There is no eGFR at which dapagliflozin must be dose-reduced. The only hard stop is dialysis initiation.

Special Populations: Diabetic Kidney Disease, Heart Failure With CKD, and Transplant

In diabetic kidney disease (DKD), dapagliflozin sits alongside RAS blockade and finerenone as part of the three-pillar approach endorsed by KDIGO and the ADA 8. DAPA-CKD enrolled 67.5% of participants with type 2 diabetes. In this subgroup, the primary endpoint hazard ratio was 0.64 (95% CI, 0.52 to 0.79), consistent with the overall trial result 3.

For patients with both heart failure and CKD (a common overlap, present in 40% to 50% of HF patients), dapagliflozin addresses both conditions with a single 10 mg daily dose. The DELIVER trial (N=6,263) extended heart failure benefits to patients with EF >40%, and a prespecified renal subgroup analysis confirmed consistent benefit across eGFR strata 11.

Kidney transplant recipients represent an evidence gap. DAPA-CKD excluded transplant patients. A small randomized trial (DAPA-Transplant, N=44) suggested dapagliflozin was safe in stable kidney transplant recipients on tacrolimus-based immunosuppression, with no significant change in tacrolimus levels over 24 weeks 12. Larger trials are needed. Current practice favors initiating SGLT2 inhibitors only in transplant recipients who are more than 12 months post-transplant with stable graft function.

Adverse Effects Specific to Low eGFR

The safety profile in renal impairment largely mirrors the general population. Genital mycotic infections remain the most common adverse event (5% to 8% of women, 2% to 4% of men), though the incidence decreases at lower eGFR because less glucosuria occurs 3.

Volume depletion is the primary concern at lower eGFR. In DAPA-CKD, volume depletion events occurred in 5.9% of dapagliflozin patients versus 4.2% with placebo 3. Patients on combination diuretic therapy (loop plus thiazide) at baseline carried the highest risk. Diabetic ketoacidosis (DKA) risk does not appear to increase in CKD, though the absolute event rate is low enough that definitive conclusions require larger datasets. Dapagliflozin showed no increased risk of hypoglycemia in DAPA-CKD, even in participants receiving insulin or sulfonylureas 3.

Dr. David Wheeler, a DAPA-CKD steering committee member, noted: "The safety signal we watched most closely was volume depletion in patients with eGFR below 30, and the excess risk was modest and manageable with routine clinical monitoring" 6.

When to Stop Dapagliflozin in Progressive CKD

The answer is later than most clinicians think. Both FDA labeling and KDIGO guidelines permit continuation below eGFR 25 (FDA) and eGFR 20 (KDIGO) once the drug has been initiated at a qualifying eGFR 2. Dialysis initiation is the definitive stopping point.

For patients approaching dialysis (eGFR 10 to 15), the clinical decision is nuanced. SGLT2 inhibitor trials did not enroll patients below eGFR 20 (EMPA-KIDNEY) or 25 (DAPA-CKD), so evidence in the eGFR 10 to 20 range comes from continuation data rather than initiation data. The theoretical risk of volume depletion and metabolic acidosis in this range is higher, and the diuretic effect of SGLT2 inhibition is minimal at very low GFR.

A reasonable approach: continue dapagliflozin in patients with eGFR 15 to 25 who tolerate it, monitor volume status and bicarbonate levels every 4 to 6 weeks, and discontinue when dialysis planning begins (typically eGFR <15 with symptoms or eGFR <10) 8.

Dapagliflozin 10 mg once daily requires no renal dose adjustment at any stage of CKD. Initiate at eGFR ≥25 per the FDA label or ≥20 per KDIGO, continue through progressive decline, and stop at dialysis. Recheck creatinine at 2 to 4 weeks, expect the hemodynamic dip, and resist the urge to discontinue a drug that trial data shows protects the kidney it appears to temporarily stress.